What happened

The most useful lesson of the week came from a deal that never traded. OPay, the SoftBank-backed payments company, priced 16 million American depositary shares at $19, the bottom of its $19 to $21 range, for expected proceeds of about $304 million and a valuation near $4 billion. The shares were due to start trading on the New York Stock Exchange on Friday, October 30 under the ticker OPAY.

They never did. According to the same report, the NYSE feed showed a halt at 3:30 p.m. New York time with news pending, after Bloomberg-reported indications had the ADSs opening between $16.25 and $16.75, below the offer price. The company then said it and its underwriters had "mutually agreed to terminate" the underwriting agreement dated October 29, so the offering would not be completed. The stated reason was an inquiry "in a foreign jurisdiction, which is being addressed through the appropriate channels." OPay has not named the jurisdiction or the subject of the inquiry.

The same Thursday night, two US biotechs priced on Nasdaq. Bambusa Therapeutics (BBTX) upsized to 10.55 million shares and priced at $16, the midpoint, for about $168.8 million. Aspen Neuroscience (ASPE) priced 9.375 million shares at $15, the bottom of a $15 to $17 range, raising $140.63 million.

The OPay deal: what we know and what we don't

The facts that are established are narrow. The deal priced, a halt came before the first trade, and the underwriting agreement was terminated by mutual consent. Startup Fortune, citing Bloomberg, names Citigroup (C), Deutsche Bank (DB) and JPMorgan Chase (JPM) as the banks that tore up the agreement. It also reports that OPay called the matter immaterial to its core business, said it expected a quick resolution, and said operations in Nigeria, Indonesia, Egypt and Pakistan were running normally. Nairametrics reports a different underwriter line-up, and the sources do not reconcile it, so treat the bank list as unsettled.

Much remains unknown. The company has not said whether it will return to the NYSE or when. Nairametrics reports that OPay still plans a secondary listing on the Nigerian Exchange. The reports we reviewed do not say how investor orders were handled after termination, and we will not guess.

The pre-IPO ownership shows who was exposed. Startup Fortune lists founder Yahui Zhou at about 21.3%, Opera at about 8.6% and SoftBank entities at about 6.6%.

Why a priced deal can still fail

Founders often treat pricing as the finish line. This week shows it is not. Between pricing and the first trade there is a short window in which the underwriting agreement can still be terminated, and that window is where OPay's deal ended. Here, the trigger appears to have been a regulatory inquiry rather than weak demand, though demand was not strong either: the bottom-of-range price and the sub-offer opening indications point to a book that was already soft.

Three practical points follow for issuers.

  • Regulatory exposure travels with you. A company operating across several jurisdictions can be stopped by an inquiry in one it calls immaterial. Disclosure counsel should map open inquiries in every operating market before launch, not at pricing.
  • Demand and certainty are separate risks. A deal can clear the book and still not close. Read the termination provisions in the underwriting agreement as closely as the price.
  • Low-end pricing leaves no cushion. With the price at the floor of the range, indications below it before the open left little room for the underwriters to support the stock.

Two biotechs, two results

The biotech pair is a cleaner read on pricing. Bambusa, an immunology company whose lead candidate targets IL-4Rα and IL-31, raised its deal size and priced at the midpoint, a sign that demand for the book exceeded the original share count. The Nasdaq debut was less friendly: IPOScoop reports the stock opened at $14.88, $1.12 below the offer price, or 7%, and the page gave no first-day close.

Aspen went the other way. It priced at the floor, but the stock opened at $14.70 and closed at $14.89, about 0.7% under its $15 IPO price. That is a soft but orderly debut. Pricing at the low end and then holding close to the offer price is what a well-supported deal at a realistic price looks like.

ValueAdd VC notes that Aspen's IPO raised less than its prior private financing, which it puts at more than $340 million. We could not confirm that private figure from a second source, so read it as that site's number. The point for biotech founders is still worth making: a public round can come in below private marks, and the market will not pay for the last private price on its own.

The upsized deal also deserves a caution. An upsize followed by a first-day open below the offer price suggests the extra shares were absorbed at the price but without a first-day premium. Founders should not assume an upsized book means a pop.

The rest of the calendar

Smaller deals continued underneath. Renaissance Capital's weekly log shows two $100 million SPAC IPOs pricing that week, BHAV Acquisition II on October 29 and SPACCircle Acquisition on October 27, plus several micro-cap filings in the $17 million to $25 million range. For the week ahead it lists only one scheduled listing, a SPAC called Football Manager SPAC (FBLLU), with smaller deals possibly added.

That is a thin calendar. It means the next few sessions are unlikely to settle the question of appetite on their own. Issuers waiting for a clean read will be watching how ASPE and BBTX trade against their offer prices, not for a wave of new pricings.

What to watch next

  • OPay's next step. Whether the company names the jurisdiction, resolves the inquiry and re-launches, and on what terms, will show how much damage a terminated deal does to a second attempt.
  • BBTX and ASPE against their offer prices. Both opened or closed below $16 and $15 respectively on day one. Trading above the IPO price over the following weeks would show the pricing was fair.
  • Underwriting-agreement language. Expect issuer counsel to push harder on termination and market-out terms after a deal that failed after pricing.
  • Whether lower-end pricing becomes the norm. Two of this week's three deals priced at the floor of their ranges.

For founders and CFOs planning a listing, the working assumption should be that a priced deal is a deal with a closing risk, and that range-floor pricing is a signal about demand, not an accident of timing. This is analysis of public reports, not investment advice.

Sources